The data analytics firm EvaluatePharma compiled the forecasts based on pharmaceutical companies’ sales projections as of December 2023. Humira, AbbVie’s best-selling anti-inflammatory drug, is notably absent from the list, as the drug lost its market exclusivity in 2023.
Here are the 10 projected best-selling drugs in 2024 and their expected global sales:
1. Keytruda (Merck) — $27.2 billion
2. Ozempic (Novo Nordisk) — $16.1 billion
3. Dupixent (Sanofi) — $13.5 billion
4. Eliquis (Bristol Myers Squibb) — $13.3 billion
5. Biktarvy (Gilead) — $12.6 billion
6. Darzalex (Johnson & Johnson) — $12 billion
7. Opdivo (Bristol Myers Squibb/Ono Pharmaceutical) — $11.3 billion
8. Comimaty (Pfizer/BioNTech) — $10.8 billion
9. Gardasil (Merck/CSL) — $10 billion
10. Skyrizi (AbbVie) — $9.9 billion
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
